Literature DB >> 14764456

Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas.

Ming Zhu Fang1, Changgong Liu, Yunlong Song, Guang-Yu Yang, Yan Nie, Jie Liao, Xin Zhao, Yutaka Shimada, Li-Dong Wang, Chung S Yang.   

Abstract

Gastrin-releasing peptide (GRP) is known as an autocrine growth factor for a number of gastrointestinal cancers. There is, however, little information on the expression of GRP in the squamous epithelia and squamous cell carcinoma, particularly in the esophagus. With a differential display approach, up-regulated GRP was observed in human esophageal squamous cell carcinoma (ESCC) samples obtained from a high-risk area for esophageal cancer, Linzhou in northern China. Up-regulation of phosphoglycerate mutase and P311 HUM (3.1) and down-regulation of keratin 13, cystatin B, endoglin and annexin I were observed. Using a reverse transcription-polymerase chain reaction (RT-PCR) method, significant over-expression of GRP was observed in 10 out of 12 ESCC samples (83.3%) and all four ESCC cell lines. With in situ hybridization, GRP mRNA expression was detected in nine out of 21 (42.8%) samples with basal cell hyperplasia (BCH), five out of seven (71.4%) samples with dysplasia (DYS) and 17 out of 24 (70.9%) ESCC samples. In contrast, GRP was expressed only in three out of 16 (18.7%) normal epithelium. Digital image analysis revealed that the mean value of GRP expression index, determined by intensity and area ratio of staining, was 0.19 in normal epithelium, 1.23 in BCH, 2.94 in DYS and 2.38 in ESCC, showing a progressive increase. Studies on ESCC cell lines showed GRP increased cell growth in a dose-dependent pattern in GRP receptor-positive ESCC cells, but not in GRP receptor-negative ESCC cells. GRP (1 mM) also increased cyclooxygenase-2 protein expression by 3.4-fold. This is the first demonstration that GRP is over-expressed in ESCC, and its over-expression may play a role in ESCC development and growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764456     DOI: 10.1093/carcin/bgh097

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

1.  Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.

Authors:  Antonella Accardo; Silvia Mannucci; Elena Nicolato; Federica Vurro; Carlo Diaferia; Pietro Bontempi; Pasquina Marzola; Giancarlo Morelli
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 2.  Gastrin-releasing peptide links stressor to cancer progression.

Authors:  Xinqiu Li; Yunfu Lv; Aihua Yuan; Zongfang Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-06       Impact factor: 4.553

3.  Phosphoglycerate Mutase 1 Promotes Cell Proliferation and Neuroblast Differentiation in the Dentate Gyrus by Facilitating the Phosphorylation of cAMP Response Element-Binding Protein.

Authors:  Hyo Young Jung; Hyun Jung Kwon; Woosuk Kim; Sung Min Nam; Jong Whi Kim; Kyu Ri Hahn; Dae Young Yoo; Moo-Ho Won; Yeo Sung Yoon; Dae Won Kim; In Koo Hwang
Journal:  Neurochem Res       Date:  2018-11-20       Impact factor: 3.996

4.  Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.

Authors:  Fenglian Ren; Hong Wu; Yunlong Lei; Haiyuan Zhang; Rui Liu; Yong Zhao; Xiancheng Chen; Dequan Zeng; Aiping Tong; Lijuan Chen; Yuquan Wei; Canhua Huang
Journal:  Mol Cancer       Date:  2010-04-19       Impact factor: 27.401

5.  Immunohistochemical examination of gastrin, gastrin precursors, and gastrin/CCK-2 receptor in human esophageal squamous cell carcinomas.

Authors:  Aping Yuan; Jinzhong Liu; Yiqing Liu; Tone Bjørnsen; Andrea Varro; Guanglin Cui
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

6.  In-frame cDNA library combined with protein complementation assay identifies ARL11-binding partners.

Authors:  Sangkyou Lee; Ilkyun Lee; Yoonsuh Jung; David McConkey; Bogdan Czerniak
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

7.  Core-shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis.

Authors:  Birju P Shah; Nicholas Pasquale; Gejing De; Tao Tan; Jianjie Ma; Ki-Bum Lee
Journal:  ACS Nano       Date:  2014-08-21       Impact factor: 15.881

8.  Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma.

Authors:  Hua Zhu; Hui Zhang; Feng Jin; Mingzhu Fang; Mark Huang; Chung S Yang; Tong Chen; Liwu Fu; Zui Pan
Journal:  Oncotarget       Date:  2014-06-15

9.  A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells.

Authors:  Anna Vert; Jessica Castro; Marc Ribó; Antoni Benito; Maria Vilanova
Journal:  Oncotarget       Date:  2016-04-05

10.  DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.

Authors:  Yan-Mei Ji; Xue-Feng Zhou; Jun Zhang; Xiang Zheng; Sheng-Bao Li; Zhi-Qiang Wei; Tao Liu; Dong-Liang Cheng; Ping Liu; Kuncheng Song; Tao Tan; Hua Zhu; Jia-Long Guo
Journal:  Oncotarget       Date:  2016-03-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.